CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Status:
RECRUITING
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on the cell surface of B cells and their precursors. During treatment, patients undergo leukapheresis, lymophodepleting chemotherapy and administration of the expanded CD19-CAR-transduced T cells.